Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505249 | 0.87 | ADRB1 (0.52) | TSHRHSD17B10KDM4EL3MBTL1MEN1 | |
| SCHEMBL1188345 | 0.86 | TSHR (0.56) | TSHRHSD17B10KDM4EL3MBTL1GAA | |
| SCHEMBL31078354 | 0.86 | TSHR (0.56) | TSHRHSD17B10KDM4EL3MBTL1GAA | |
| SCHEMBL30628273 | 0.86 | CYP3A4 (0.61) | TSHRKDM4ECYP3A4L3MBTL1LMNA | |
| SCHEMBL4271221 | 0.86 | CYP3A4 (0.61) | TSHRKDM4ECYP3A4L3MBTL1LMNA | |
| SCHEMBL28826108 | 0.84 | KEAP1 (0.46) | HSD17B10KDM4EFFAR4KEAP1KMT2A | |
| SCHEMBL20471860 | 0.84 | PTPN11 (0.52) | TSHRCYP3A4LMNAMEN1KMT2A | |
| SCHEMBL1546433 | 0.83 | TSHR (0.54) | TSHRHSD17B10KDM4ECYP3A4GAA | |
| Hydrochloric Acid SCHEMBL30779134 | 0.83 | MKNK1 (0.52) | TSHRKDM4ECYP3A4L3MBTL1LMNA | |
| SCHEMBL25794823 | 0.83 | TDP1 (0.62) | TSHRHSD17B10KDM4ECYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250170100-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2025010394-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF INFLAMMATORY CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025010392-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4457213-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | Psy Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024215863-A2 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-2794608-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| EP-2794608-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2674434-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013091773-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013091773-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2607364-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | Ares Trading S.A. (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2607364-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | Ares Trading S.A. (CH) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | TSHR 3929/4885HSD17B10 301/4885KDM4E 2578/4885 |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LPL | TSHR 4535/4885HSD17B10 81/4885KDM4E 1086/4885 |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | MGLL, PNLIP, LIPC | TSHR 3929/4885HSD17B10 301/4885KDM4E 2578/4885 |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | TSHR 4339/4885HSD17B10 505/4885KDM4E 1457/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | TSHR 2854/4885HSD17B10 806/4885KDM4E 2173/4885 |
| US-20250170100-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | TSHR 2042/4885HSD17B10 248/4885KDM4E 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.